Nervous System News and Research

Latest Nervous System News and Research

Study shows how GLP-1 receptor agonists modify the brain's response to food

Gut hormone-based medications used to treat diabetes, such as GLP-1 receptor agonists, have also been shown to reduce body weight. Researchers have been working to understand how. This study, presented today at the American Diabetes Association's 75th Scientific Sessions, sheds light on how GLP-1 receptor agonists alter the brain's response to food, possibly reducing cravings and increasing satisfaction while eating.

9 Jun 2015

Researchers discover initiation process of dendritic spines

Researchers from the University of Helsinki, ETH Zürich, Aix-Marseille and the German Mouse Clinic teamed up to investigate the initiation process of dendritic spines. They discovered that protein called MIM bends the plasma membrane to aid the formation of dendritic spines from the surface of the neuronal dendrite.

5 Jun 2015

Study can help spur beneficial lifestyle changes in patients to reduce Alzheimer's risk

Armed with new knowledge about how neurodegenerative diseases alter brain structures, increasing numbers of neurologists, psychiatrists and other clinicians are adopting quantitative brain imaging as a tool to measure and help manage cognitive declines in patients. These imaging findings can help spur beneficial lifestyle changes in patients to reduce risk for Alzheimer's disease.

5 Jun 2015

Delay of gratification linked to white matter connectivity in the dorsal prefrontal cortex

The ability to delay gratification in chimpanzees is linked to how specific structures of the brain are connected and communicate with each other, according to researchers at Georgia State University and Kennesaw State University.

5 Jun 2015

Actavis receives FDA approval to market NATRELLE INSPIRA round gel-filled textured breast implants

Actavis plc, which recently completed the acquisition of Allergan, Inc., today announced that the company has received approval from the U.S. Food and Drug Administration to market NATRELLE INSPIRA round gel-filled textured breast implants, offering women undergoing reconstruction, augmentation or revision surgery another breast shaping option for a customized result.

5 Jun 2015

Newly discovered nerve cells trigger locomotion, supply the brain with speed-related information

Scientists at the German Center for Neurodegenerative Diseases and the University of Bonn led by Prof. Stefan Remy report on this in the journal "Neuron". Their investigations give new insights into the workings of spatial memory. Furthermore, they could also help improve our understanding of movement related symptoms associated with Parkinson's disease.

4 Jun 2015

Scientists uncover why some people more prone to major depression

Scientists are beginning to unwrap the biology behind why some people are more prone to major depression and other psychiatric disorders than others when experiencing stressful life events. The researchers found that cellular activity in response to stress hormone receptor activation differs from individual to individual.

4 Jun 2015

Researchers examine neuroimaging findings in children with sports-related concussions

Researchers from the Canada North Concussion Network in Manitoba examined neuroimaging studies obtained in children and adolescents with sports-related concussions and found that the images appeared normal in 78% of cases.

3 Jun 2015

MGH researchers develop bioartificial replacement limbs suitable for transplantation

A team of Massachusetts General Hospital investigators has made the first steps towards development of bioartificial replacement limbs suitable for transplantation. In their report, which has been published online in the journal Biomaterials, the researchers describe using an experimental approach previously used to build bioartificial organs to engineer rat forelimbs with functioning vascular and muscle tissue.

3 Jun 2015

FDA approves Actavis ANDA for guaifenesin/pseudoephedrine tablets to relieve chest congestion

Actavis plc and its partner Perrigo Company plc announced today that Actavis has received U.S. Food and Drug Administration approval for its Abbreviated New Drug Application for guaifenesin/pseudoephedrine tablets and that Perrigo will begin shipments in time for the cough/cold season to its retail and wholesale customers in the U.S. The product will be packaged and marketed under store and proprietary brands and will be a high quality, value alternative to Mucinex® D tablets.

2 Jun 2015

New study on vestibulo-ocular dysfunction in pediatric sports-related concussion

Researchers from the Canada North Concussion Network in Manitoba investigated the frequency of vestibulo-ocular dysfunction in children and adolescents with sports-related concussion and found that its presence was predictive of a prolonged recovery.

2 Jun 2015

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Upsher-Smith Laboratories, Inc. announced that it has received U.S. Food and Drug Administration approval of a supplemental new drug application (sNDA) for Qudexy XR (topiramate) extended-release capsules for use as initial monotherapy in patients two years of age and older who are experiencing partial-onset seizures (POS) or primary generalized tonic-clonic seizures.

2 Jun 2015

Actavis acquires Auden Mckenzie

Actavis plc today announced that it has completed its acquisition of Auden Mckenzie Holdings Limited, a dynamic and fast growing company focused on the development, licensing and marketing of niche generic medicines and proprietary brands in the UK.

1 Jun 2015

Scientists develop human cortical spheroids

A patient tormented by suicidal thoughts gives his psychiatrist a few strands of his hair. She derives stem cells from them to grow budding brain tissue harboring the secrets of his unique illness in a petri dish. She uses the information to genetically engineer a personalized treatment to correct his brain circuit functioning. Just Sci-fi? Yes, but...

1 Jun 2015

Roche’s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

Data to be presented at the 51st Annual Meeting of the American Society of Clinical Oncology suggest that the investigational immunotherapy MPDL3280A may double the likelihood of overall survival in the study period (HR=0.47), compared with docetaxel chemotherapy, in individuals with non-small cell lung cancer (NSCLC) who expressed the highest levels of PD-L1 (a receptor present on cancer cells).

30 May 2015

New study shows stem cell treatments promote faster healing in primates with spinal cord injury

A new study appearing today in STEM CELLS Translational Medicine, designed to test how stem cell injections affect primates with spinal cord injury (SCI), showed the treatments significantly improved the animals’ motor function recovery and promoted faster healing, too. The researchers call their findings a step forward toward the goal of improving outcomes for humans with chronic SCI.

30 May 2015

Main culprit of Alzheimer's disease causes memory loss

The study, published May 29 in the open access Nature Publishing Group journal Scientific Reports, reveals a direct link between the main culprit of Alzheimer's disease and memory loss.

29 May 2015

People with MS have much greater risk of dying younger compared to people without MS

New research suggests people with multiple sclerosis (MS) may have double the risk of dying early compared to people without MS, with those younger than 59 at a three times higher risk. The study is published in the May 27, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

28 May 2015

Novartis launches ‘24 Life Hacks in 24 hours’ showing commitment to help people with MS access guidance and advice

World MS Day was created by the Multiple Sclerosis International Foundation (MSIF) in 2009 to raise global awareness of MS...

28 May 2015

Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment

Actavis plc announced today that VIBERZI (eluxadoline) was approved by the Food and Drug Administration as a twice-daily, oral treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D). VIBERZI (eluxadoline) has mixed opioid receptor activity, it is a mu receptor agonist, a delta receptor antagonist, and a kappa receptor agonist.

28 May 2015

Nervous System News and Research

Latest Nervous System News and Research

Study shows how GLP-1 receptor agonists modify the brain's response to food

Researchers discover initiation process of dendritic spines

Study can help spur beneficial lifestyle changes in patients to reduce Alzheimer's risk

Delay of gratification linked to white matter connectivity in the dorsal prefrontal cortex

Actavis receives FDA approval to market NATRELLE INSPIRA round gel-filled textured breast implants

Newly discovered nerve cells trigger locomotion, supply the brain with speed-related information

Scientists uncover why some people more prone to major depression

Researchers examine neuroimaging findings in children with sports-related concussions

MGH researchers develop bioartificial replacement limbs suitable for transplantation

FDA approves Actavis ANDA for guaifenesin/pseudoephedrine tablets to relieve chest congestion

New study on vestibulo-ocular dysfunction in pediatric sports-related concussion

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Actavis acquires Auden Mckenzie

Scientists develop human cortical spheroids

Roche’s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

New study shows stem cell treatments promote faster healing in primates with spinal cord injury

Main culprit of Alzheimer's disease causes memory loss

People with MS have much greater risk of dying younger compared to people without MS

Novartis launches ‘24 Life Hacks in 24 hours’ showing commitment to help people with MS access guidance and advice

Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment

Everything you need to know about epilepsy eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Nervous System News and Research

Latest Nervous System News and Research

Everything you need to know about epilepsy eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in